Skip to Main Content

Paper Details

Why do we not have more drugs approved for MDS? A critical viewpoint on novel drug development in MDS.
Blood Rev
3
2023
Author NameAffiliation
Richard M StoneDana-Farber Cancer Institute
Daniel J DeAngeloDana-Farber Cancer Institute
  • 1 - 2

Datasets

Release 1.2